Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
Amino acid PET scans are outpacing MRI in detecting early treatment responses in IDH-mutant glioma patients on vorasidenib. Interim data from a multicenter European study show PET identified responses in a median of 4 months vs. 8 months with standard MRI. The findings suggest serial PET imaging could become a key tool for monitoring this brain cancer treatment.
For patients with IDH-mutant glioma on vorasidenib (Voranigo), waiting for MRI to show tumor changes may no longer be the only option. Interim results from a retrospective, multicenter European study presented at the 2026 SNO Annual Meeting found that serial amino acid PET scans detected metabolic treatment responses significantly earlier than structural MRI — a meaningful advantage given how slowly tumor volume shifts on conventional imaging.
The study analyzed 50 patients across hospitals in Germany and the Netherlands. Using PET RANO 1.0 criteria, 29% of patients showed a partial response vs. just 6% under standard RANO 2.0 (MRI-based) criteria. The key driver of early PET-based classification was change in metabolic tumor volume (MTV), which ranged from a complete −100% reduction to increases exceeding 390% in progressive disease cases.
By the Numbers:
Why it matters: Vorasidenib was FDA-approved in 2024 for grade 2 IDH-mutant glioma, but tracking its effectiveness has been hampered by slow structural MRI changes. Serial amino acid PET could offer clinicians a faster, more sensitive window into whether the drug is working — potentially enabling earlier treatment decisions.
